| Renal Cell Carcinoma
Cabometyx vs Inlyta
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Cabometyx vs Inlyta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInlyta has a higher rate of injection site reactions vs Cabometyx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Inlyta but not Cabometyx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cabometyx
Inlyta
At A Glance
Oral
Once daily
Tyrosine kinase inhibitor
Oral
Twice daily
VEGFR tyrosine kinase inhibitor
Indications
- Renal Cell Carcinoma
- Liver carcinoma
- Well Differentiated Pancreatic Endocrine Neoplasm
- Neuroendocrine Tumors
- Renal Cell Carcinoma
Dosing
Renal Cell Carcinoma (single agent) 60 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (+ nivolumab) 40 mg orally once daily in combination with nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks, or subcutaneous formulations) until disease progression or unacceptable toxicity.
Liver carcinoma 60 mg orally once daily until disease progression or unacceptable toxicity.
Differentiated Thyroid Cancer, Well Differentiated Pancreatic Endocrine Neoplasm, Neuroendocrine Tumors 60 mg orally once daily for adults and pediatric patients >=40 kg; 40 mg orally once daily for pediatric patients 12 years and older with bodyweight <40 kg, until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (first-line, with avelumab) 5 mg orally twice daily combined with avelumab 800 mg IV every 2 weeks; dose escalation may be considered at intervals of 2 weeks or longer.
Renal Cell Carcinoma (first-line, with pembrolizumab) 5 mg orally twice daily combined with pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks IV; dose escalation may be considered at intervals of 6 weeks or longer.
Renal Cell Carcinoma (second-line, single agent) Starting dose 5 mg orally twice daily approximately 12 hours apart, with or without food; doses may be increased to 7 mg or 10 mg twice daily based on tolerability, or reduced to 3 mg or 2 mg twice daily for adverse reactions.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Diarrhea, fatigue, palmar-plantar erythrodysesthesia, hypertension, decreased appetite, nausea, vomiting, weight decreased, constipation, stomatitis, rash, hypothyroidism, musculoskeletal pain.
Serious Hemorrhage, perforations and fistulas, thromboembolic events, hypertensive crisis, cardiac failure, hepatotoxicity, adrenal insufficiency, proteinuria, osteonecrosis of the jaw, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypocalcemia.
Postmarketing Arterial (including aortic) aneurysms, dissections, and rupture.
Most common (>=20%) Diarrhea, fatigue, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, musculoskeletal pain, constipation
Serious Hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, hepatotoxicity
Postmarketing Arterial aneurysms, dissections, and rupture (including aortic)
Pharmacology
Cabozantinib is a tyrosine kinase inhibitor that inhibits MET, VEGFR-1/-2/-3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2 - receptor tyrosine kinases involved in oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Axitinib is a selective inhibitor of receptor tyrosine kinases including VEGFR-1, VEGFR-2, and VEGFR-3, which are implicated in pathologic angiogenesis, tumor growth, and cancer progression; VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cabometyx
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Inlyta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Cabometyx
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Inlyta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (3/8)
Humana
Cabometyx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Inlyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cabometyx.
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CabometyxView full Cabometyx profile
InlytaView full Inlyta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.